A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Pazopanib (Primary) ; Paclitaxel
- Indications Malignant melanoma
- Focus Therapeutic Use
- 12 Jan 2018 Planned End Date changed from 1 Jul 2018 to 1 Jan 2019.
- 12 Jan 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 06 Dec 2016 Status changed from recruiting to active, no longer recruiting.